Status:
COMPLETED
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
20+ years
Brief Summary
This is a multicenter retrospective study designed to compare overall survival (OS) by PD-L1 expression status in patients with RCC who have received systemic chemotherapy for recurrent or metastatic ...
Eligibility Criteria
Inclusion
- 1\. Written informed consent for this study. In the case obtaining written informed consent is difficult due to death, change of address, and so on, the opt-out consent is accepted by giving patients or their relatives notification regarding the usage of their clinical information and surgical samples for the research.
- 2\. Age at nephrectomy≧20 years
- Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
Exclusion
- 1\. Malignancies other than RCC is co-existed from the time of nephrectomy and death.
- 2\. Treatment with anti-CTLA-4 antibody, anti-PD-1/PD-L1 antibodies as first-line therapy for recurrent or metastatic RCC.
Key Trial Info
Start Date :
December 16 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 21 2021
Estimated Enrollment :
830 Patients enrolled
Trial Details
Trial ID
NCT03748901
Start Date
December 16 2018
End Date
July 21 2021
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aichi Medical University
Nagoya, Aichi-ken, Japan, 480-1103